138 related articles for article (PubMed ID: 34778724)
1. Clinical HDAC Inhibitors Are Effective Drugs to Prevent the Entry of SARS-CoV2.
Liu K; Zou R; Cui W; Li M; Wang X; Dong J; Li H; Li H; Wang P; Shao X; Su W; Chan HCS; Li H; Yuan S
ACS Pharmacol Transl Sci; 2020 Dec; 3(6):1361-1370. PubMed ID: 34778724
[TBL] [Abstract][Full Text] [Related]
2. 1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection.
Chen RH; Yang LJ; Hamdoun S; Chung SK; Lam CW; Zhang KX; Guo X; Xia C; Law BYK; Wong VKW
Front Pharmacol; 2021; 12():634176. PubMed ID: 33897423
[TBL] [Abstract][Full Text] [Related]
3. Drug designing against NSP15 of SARS-COV2 via high throughput computational screening and structural dynamics approach.
Batool A; Bibi N; Amin F; Kamal MA
Eur J Pharmacol; 2021 Feb; 892():173779. PubMed ID: 33275961
[TBL] [Abstract][Full Text] [Related]
4. A Reminder of Skin Cancer During the COVID-19 Pandemic.
Šitum M; Filipović N; Buljan M
Acta Dermatovenerol Croat; 2021 Apr; 291(1):58. PubMed ID: 34477068
[TBL] [Abstract][Full Text] [Related]
5. The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach.
Di Paola L; Hadi-Alijanvand H; Song X; Hu G; Giuliani A
J Proteome Res; 2020 Nov; 19(11):4576-4586. PubMed ID: 32551648
[TBL] [Abstract][Full Text] [Related]
6. Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis.
Hou Y; Ge S; Li X; Wang C; He H; He L
Chem Biol Interact; 2021 Apr; 338():109420. PubMed ID: 33609497
[TBL] [Abstract][Full Text] [Related]
7. Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles.
Chen CZ; Xu M; Pradhan M; Gorshkov K; Petersen JD; Straus MR; Zhu W; Shinn P; Guo H; Shen M; Klumpp-Thomas C; Michael SG; Zimmerberg J; Zheng W; Whittaker GR
ACS Pharmacol Transl Sci; 2020 Dec; 3(6):1165-1175. PubMed ID: 33330839
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2.
Bilal M; Iqbal HMN
Hum Vaccin Immunother; 2020 Dec; 16(12):3034-3042. PubMed ID: 32845742
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of L-Type Calcium Channels Show Therapeutic Potential for Treating SARS-CoV-2 Infections by Preventing Virus Entry and Spread.
Straus MR; Bidon MK; Tang T; Jaimes JA; Whittaker GR; Daniel S
ACS Infect Dis; 2021 Oct; 7(10):2807-2815. PubMed ID: 34498840
[TBL] [Abstract][Full Text] [Related]
10. GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.
Rudd CE
Front Immunol; 2020; 11():1638. PubMed ID: 32695123
[TBL] [Abstract][Full Text] [Related]
11. Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease.
Wang SC; Chen Y; Wang YC; Wang WJ; Yang CS; Tsai CL; Hou MH; Chen HF; Shen YC; Hung MC
Am J Cancer Res; 2020; 10(12):4538-4546. PubMed ID: 33415017
[TBL] [Abstract][Full Text] [Related]
12. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine.
Schloer S; Brunotte L; Goretzko J; Mecate-Zambrano A; Korthals N; Gerke V; Ludwig S; Rescher U
Emerg Microbes Infect; 2020 Dec; 9(1):2245-2255. PubMed ID: 32975484
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Biological Evaluation of Honokiol Derivatives Bearing 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)oxazol-2(3H)-ones as Potential Viral Entry Inhibitors against SARS-CoV-2.
Guo Y; Meng JR; Liu JZ; Xu T; Zheng ZY; Jiang ZH; Bai LP
Pharmaceuticals (Basel); 2021 Aug; 14(9):. PubMed ID: 34577585
[TBL] [Abstract][Full Text] [Related]
14. Tumor Necrosis Factor-Alpha Exacerbates Viral Entry in SARS-CoV2-Infected iPSC-Derived Cardiomyocytes.
Lee CY; Huang CH; Rastegari E; Rengganaten V; Liu PC; Tsai PH; Chin YF; Wu JR; Chiou SH; Teng YC; Lee CW; Liang Y; Chen AY; Hsu SC; Hung YJ; Sun JR; Chien CS; Chien Y
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576032
[TBL] [Abstract][Full Text] [Related]
15. Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study.
Vijayan V; Pant P; Vikram N; Kaur P; Singh TP; Sharma S; Sharma P
J Biomol Struct Dyn; 2021 Oct; 39(17):6713-6727. PubMed ID: 32741322
[TBL] [Abstract][Full Text] [Related]
16. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.
Tandon R; Sharp JS; Zhang F; Pomin VH; Ashpole NM; Mitra D; McCandless MG; Jin W; Liu H; Sharma P; Linhardt RJ
J Virol; 2021 Jan; 95(3):. PubMed ID: 33173010
[TBL] [Abstract][Full Text] [Related]
17. Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods.
Ginex T; Garaigorta U; Ramírez D; Castro V; Nozal V; Maestro I; García-Cárceles J; Campillo NE; Martinez A; Gastaminza P; Gil C
Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33917313
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
Giorgi M; Cardarelli S; Ragusa F; Saliola M; Biagioni S; Poiana G; Naro F; Massimi M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32727145
[TBL] [Abstract][Full Text] [Related]
19. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
20. [About possible medications to treat SARS-CoV-2 infection, which causes COVID-19: is there any hope?].
Torres-López J
Rev Med Inst Mex Seguro Soc; 2020 May; 58(3):226-228. PubMed ID: 34002978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
